Cargando…

Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study

INTRODUCTION: In the real-world APPRECIATE study (NCT02740218), most patients with psoriasis demonstrated notable improvements on disease severity measures and reported clinically meaningful treatment benefits with apremilast. OBJECTIVE: We aim to further describe patient-relevant needs and benefits...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Toni Maria, Blome, Christine, Kleyn, C. Elise, Conrad, Curdin, Sator, Paul G., Ståhle, Mona, Eyerich, Kilian, Radtke, Marc Alexander, Bundy, Christine, Cordey, Myriam, Griffiths, Christopher E. M., Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776914/
https://www.ncbi.nlm.nih.gov/pubmed/34813044
http://dx.doi.org/10.1007/s13555-021-00628-3
_version_ 1784636941407354880
author Klein, Toni Maria
Blome, Christine
Kleyn, C. Elise
Conrad, Curdin
Sator, Paul G.
Ståhle, Mona
Eyerich, Kilian
Radtke, Marc Alexander
Bundy, Christine
Cordey, Myriam
Griffiths, Christopher E. M.
Augustin, Matthias
author_facet Klein, Toni Maria
Blome, Christine
Kleyn, C. Elise
Conrad, Curdin
Sator, Paul G.
Ståhle, Mona
Eyerich, Kilian
Radtke, Marc Alexander
Bundy, Christine
Cordey, Myriam
Griffiths, Christopher E. M.
Augustin, Matthias
author_sort Klein, Toni Maria
collection PubMed
description INTRODUCTION: In the real-world APPRECIATE study (NCT02740218), most patients with psoriasis demonstrated notable improvements on disease severity measures and reported clinically meaningful treatment benefits with apremilast. OBJECTIVE: We aim to further describe patient-relevant needs and benefits and patient satisfaction with apremilast, including subgroup analyses based on patient characteristics. METHODS: APPRECIATE, a multinational, retrospective, cross-sectional study, enrolled patients with chronic plaque psoriasis who started apremilast according to the European label. Patient Benefit Index (PBI; range 0 (no patient-relevant benefit) to 4 (maximum patient-relevant benefit), global PBI score ≥ 1 indicating minimum patient-relevant benefit and ≥ 3 indicating high benefit) and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9; range 0–100) were assessed 6 (± 1) months after apremilast initiation and summarized descriptively. Relationships between global PBI and TSQM-9 assessments were analyzed by Pearson correlations. RESULTS: Of 480 enrolled patients, 347 (72.3%) had remained on apremilast at 6 (± 1) months; 90.9% (300/330) achieved global PBI score ≥ 1. Mean (standard deviation) global PBI score was 2.8 (1.2). Higher achievement of global PBI score ≥ 3 was observed in patients with no prior treatments (61.1% (22/36)) or prior phototherapy (64.6% (42/65)) versus prior conventional systemic (54.4% (100/184)) or biologic (38.6% (17/44)) treatment. Strong correlations were observed between the global PBI score and the TSQM-9 global satisfaction and effectiveness subscale scores. CONCLUSION: Patients continuing apremilast for 6 (± 1) months in APPRECIATE reported patient-relevant treatment benefits. Findings suggest that receiving apremilast earlier versus later in treatment management is consistent with greater improvements in patient-relevant treatment outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-021-00628-3.
format Online
Article
Text
id pubmed-8776914
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-87769142022-02-02 Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study Klein, Toni Maria Blome, Christine Kleyn, C. Elise Conrad, Curdin Sator, Paul G. Ståhle, Mona Eyerich, Kilian Radtke, Marc Alexander Bundy, Christine Cordey, Myriam Griffiths, Christopher E. M. Augustin, Matthias Dermatol Ther (Heidelb) Original Research INTRODUCTION: In the real-world APPRECIATE study (NCT02740218), most patients with psoriasis demonstrated notable improvements on disease severity measures and reported clinically meaningful treatment benefits with apremilast. OBJECTIVE: We aim to further describe patient-relevant needs and benefits and patient satisfaction with apremilast, including subgroup analyses based on patient characteristics. METHODS: APPRECIATE, a multinational, retrospective, cross-sectional study, enrolled patients with chronic plaque psoriasis who started apremilast according to the European label. Patient Benefit Index (PBI; range 0 (no patient-relevant benefit) to 4 (maximum patient-relevant benefit), global PBI score ≥ 1 indicating minimum patient-relevant benefit and ≥ 3 indicating high benefit) and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9; range 0–100) were assessed 6 (± 1) months after apremilast initiation and summarized descriptively. Relationships between global PBI and TSQM-9 assessments were analyzed by Pearson correlations. RESULTS: Of 480 enrolled patients, 347 (72.3%) had remained on apremilast at 6 (± 1) months; 90.9% (300/330) achieved global PBI score ≥ 1. Mean (standard deviation) global PBI score was 2.8 (1.2). Higher achievement of global PBI score ≥ 3 was observed in patients with no prior treatments (61.1% (22/36)) or prior phototherapy (64.6% (42/65)) versus prior conventional systemic (54.4% (100/184)) or biologic (38.6% (17/44)) treatment. Strong correlations were observed between the global PBI score and the TSQM-9 global satisfaction and effectiveness subscale scores. CONCLUSION: Patients continuing apremilast for 6 (± 1) months in APPRECIATE reported patient-relevant treatment benefits. Findings suggest that receiving apremilast earlier versus later in treatment management is consistent with greater improvements in patient-relevant treatment outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-021-00628-3. Springer Healthcare 2021-11-23 /pmc/articles/PMC8776914/ /pubmed/34813044 http://dx.doi.org/10.1007/s13555-021-00628-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Klein, Toni Maria
Blome, Christine
Kleyn, C. Elise
Conrad, Curdin
Sator, Paul G.
Ståhle, Mona
Eyerich, Kilian
Radtke, Marc Alexander
Bundy, Christine
Cordey, Myriam
Griffiths, Christopher E. M.
Augustin, Matthias
Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
title Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
title_full Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
title_fullStr Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
title_full_unstemmed Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
title_short Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
title_sort real-world experience of patient-relevant benefits and treatment satisfaction with apremilast in patients with psoriasis: an analysis of the appreciate study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776914/
https://www.ncbi.nlm.nih.gov/pubmed/34813044
http://dx.doi.org/10.1007/s13555-021-00628-3
work_keys_str_mv AT kleintonimaria realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT blomechristine realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT kleyncelise realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT conradcurdin realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT satorpaulg realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT stahlemona realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT eyerichkilian realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT radtkemarcalexander realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT bundychristine realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT cordeymyriam realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT griffithschristopherem realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy
AT augustinmatthias realworldexperienceofpatientrelevantbenefitsandtreatmentsatisfactionwithapremilastinpatientswithpsoriasisananalysisoftheappreciatestudy